Ami V Patel1, Gunnar Johansson1, Melissa C Colbert1, Biplab Dasgupta1, Nancy Ratner1. 1. Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio, USA (A.V.P., N.R.); Division of Oncology, Cincinnati Children's Hospital, Cincinnati, Ohio, USA (B.D.); Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden (G.J.); Assistant Director for Compliance, Office of Intramural Research, National Institute of Health (M.C.C.).
Abstract
BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas with minimal therapeutic opportunities. We observed that lipid droplets (LDs) accumulate in human MPNST cell lines and in primary human tumor samples. The goal of this study was to investigate the relevance of lipid metabolism to MPNST survival and as a possible therapeutic target. METHODS: Based on preliminary findings that MPNSTs accumulate LDs, we hypothesized that a deregulated lipid metabolism supports MPNST cell survival/proliferation rate. To test this, we examined respiration, role of fatty acid oxidation (FAO), and the enzyme fatty acid synthase involved in de novo fatty acid synthesis in MPNSTs using both genetic and pharmacological tools. RESULTS: We demonstrate that LDs accumulate in MPNST cell lines, primary human and mouse MPNST tumors, and neural crest cells. LDs from MPNST cells disappear on lipid deprivation, indicating that LDs can be oxidized as a source of energy. Inhibition of FAO decreased oxygen consumption and reduced MPNST survival, indicating that MPNST cells likely metabolize LDs through active FAO. FAO inhibition reduced oxygen consumption and survival even in the absence of exogenous lipids, indicating that lipids synthesized de novo can also be oxidized. Consequently, inhibition of de novo fatty acid synthesis, which is overexpressed in human MPNST cell lines, effectively reduced MPNST survival and delayed induction of tumor growth in vivo. CONCLUSION: Our results show that MPNSTs depend on lipid metabolic pathways and suggest that disrupting lipid metabolism could be a potential new strategy for the development of MPNST therapeutics.
BACKGROUND:Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas with minimal therapeutic opportunities. We observed that lipid droplets (LDs) accumulate in human MPNST cell lines and in primary humantumor samples. The goal of this study was to investigate the relevance of lipid metabolism to MPNST survival and as a possible therapeutic target. METHODS: Based on preliminary findings that MPNSTs accumulate LDs, we hypothesized that a deregulated lipid metabolism supports MPNST cell survival/proliferation rate. To test this, we examined respiration, role of fatty acid oxidation (FAO), and the enzyme fatty acid synthase involved in de novo fatty acid synthesis in MPNSTs using both genetic and pharmacological tools. RESULTS: We demonstrate that LDs accumulate in MPNST cell lines, primary human and mouseMPNST tumors, and neural crest cells. LDs from MPNST cells disappear on lipid deprivation, indicating that LDs can be oxidized as a source of energy. Inhibition of FAO decreased oxygen consumption and reduced MPNST survival, indicating that MPNST cells likely metabolize LDs through active FAO. FAO inhibition reduced oxygen consumption and survival even in the absence of exogenous lipids, indicating that lipids synthesized de novo can also be oxidized. Consequently, inhibition of de novo fatty acid synthesis, which is overexpressed in human MPNST cell lines, effectively reduced MPNST survival and delayed induction of tumor growth in vivo. CONCLUSION: Our results show that MPNSTs depend on lipid metabolic pathways and suggest that disrupting lipid metabolism could be a potential new strategy for the development of MPNST therapeutics.
Authors: Ami V Patel; David Eaves; Walter J Jessen; Tilat A Rizvi; Jeffrey A Ecsedy; Mark G Qian; Bruce J Aronow; John P Perentesis; Eduard Serra; Timothy P Cripe; Shyra J Miller; Nancy Ratner Journal: Clin Cancer Res Date: 2012-07-18 Impact factor: 12.531
Authors: T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius Journal: Am J Hum Genet Date: 2003-03-26 Impact factor: 11.025
Authors: Patricia M Alli; Michael L Pinn; Elizabeth M Jaffee; Jill M McFadden; Francis P Kuhajda Journal: Oncogene Date: 2005-01-06 Impact factor: 9.867
Authors: Cory M Johannessen; Bryan W Johnson; Sybil M Genther Williams; Annie W Chan; Elizabeth E Reczek; Ryan C Lynch; Matthew J Rioth; Andrea McClatchey; Sandra Ryeom; Karen Cichowski Journal: Curr Biol Date: 2007-12-27 Impact factor: 10.834
Authors: Gunnar Johansson; Yonatan Y Mahller; Margaret H Collins; Mi-Ok Kim; Takahiro Nobukuni; John Perentesis; Timothy P Cripe; Heidi A Lane; Sara C Kozma; George Thomas; Nancy Ratner Journal: Mol Cancer Ther Date: 2008-05 Impact factor: 6.261
Authors: Peter Pytel; Theodore Karrison; James H Tonsgard; Thomas Krausz; Anthony G Montag Journal: Int J Surg Pathol Date: 2009-12-24 Impact factor: 1.271
Authors: Christina C Westhoff; Janice Mrozinski; Ina Riedel; Hans W Heid; Roland Moll Journal: J Cancer Res Clin Oncol Date: 2016-09-19 Impact factor: 4.553
Authors: Robert J Allaway; Matthew D Wood; Sondra L Downey; Stephanie J Bouley; Nicole A Traphagen; Jason D Wells; Jaya Batra; Sir Norman Melancon; Carol Ringelberg; William Seibel; Nancy Ratner; Yolanda Sanchez Journal: Oncotarget Date: 2017-07-18
Authors: Diogo Lisbôa Basto; Gustavo de Souza Vieira; Raquel M Andrade-Losso; Paula Nascimento Almeida; Vincent M Riccardi; Rafaela Elvira Rozza-de-Menezes; Karin Soares Cunha Journal: Orphanet J Rare Dis Date: 2022-09-05 Impact factor: 4.303